Agenus(US:AGEN) Prnewswire·2024-09-11 18:25Core Viewpoint - Edelson Lechtzin LLP is investigating securities fraud claims on behalf of investors of Agenus, Inc. for the period between January 23, 2023, and July 17, 2024, due to alleged misleading statements regarding the company's business and product efficacy [1][3]. Company Overview - Agenus, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on discovering immune-oncology products. Key product candidates include balstilimab for second-line cervical cancer and botensilimab for pancreatic cancer and melanoma. The company is also exploring a combination therapy of botensilimab and balstilimab for metastatic colorectal cancer [2]. Securities Fraud Claims - The Complaint alleges that during the Class Period, Agenus's Defendants made materially false and misleading statements about the effectiveness of the combination therapy of botensilimab and balstilimab, leading to overstated clinical results and regulatory prospects [3]. Stock Price Impact - Following a statement from Agenus regarding its meeting with the FDA, which recommended against submitting results for accelerated approval due to insufficient response rates, the company's stock price dropped by $10.43 per share, or 58.83%, closing at $7.30 per share on July 18, 2024 [4].